AusperBio Secures $37 Million Series A Funding to Accelerate Development of Hepatitis B Therapy
AusperBio Therapeutics, Inc., a pioneering biotechnology firm focused on targeted oligonucleotide therapies for chronic hepatitis B (CHB), has announced the successful completion of a $37 million Series A financing round. This funding, spearheaded by existing investor InnoPinnacle Fund and bolstered by new investors including Yuanbio Venture Capital, Qiming Venture Partners, Hankang Capital, and Genesis Capital,…